Systemic sclerosis & Raynaud's
Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy
Authors' conclusion
ASCS patients meeting ASTIS and/or SCOT inclusion criteria who were not treated with ASCT have similar EFS at 4 years as patients receiving ASCT and better EFS than those receiving cyclophosphamide in the ASTIS and SCOT trials.
Study context
- Population
- Australian patients with diffuse cutaneous systemic sclerosis (dcSSc) in the multicentre Australian Scleroderma Cohort Study meeting eligibility criteria for autologous stem cell transplant (ASCT) trials but not treated with ASCTdcSSc in the Australian Scleroderma Cohort Study (ASCS)
- Participants
- 492 patients
- Exposure
- ASCS patients with dcSSc meeting ASTIS or SCOT inclusion criteria, not treated with ASCT
- ASTISn = 56
- SCOTn = 30
- Outcome
- EFS (survival without cardiac, renal, or pulmonary failure or death)
- Follow-up
- 4 years
Methodological detailsmulticentre, ASCS patients who had already undergone transplantation were excluded from analysis
- Multicentre
- ASCS patients who had already undergone transplantation were excluded from analysis
Main finding
As reported in the abstract
EFS
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| EFS in patients meeting inclusion but also exclusion criteria (excluded due to severe organ manifestations) · 4 years | ASTIS inclusion + exclusion criteria 46.7% · SCOT inclusion + exclusion criteria 45.7% |
| Proportion of ASCS dcSSc patients meeting trial inclusion criteria | ASTIS-eligible 11.4% · SCOT-eligible 6.1% |
- Event-free survival (EFS) in patients meeting inclusion but also exclusion criteria (excluded due to severe organ manifestations): 11 additional patients met ASTIS or SCOT inclusion criteria but were excluded
Original publication
Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy. Arthritis Rheumatol. Published 8 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →